CORBEVAX®, A COVID19 VACCINE DEVELOPED BY BIO E-INDIA BASED ON THE RBD PROTEIN ANTIGEN TECHNOLOGY FROM TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT, RECEIVES WORLD HEALTH ORGANIZATION EMERGENCY USE LISTING APPROVAL
HOUSTON, Jan. 22, 2024 /PRNewswire/ -- Texas Children's Hospital announces today that Biological E's CORBEVAX®, a traditional, recombinant protein-based COVID-19 vaccine has received World Health Organization (WHO) approval under Emergency Use Listing (EUL). CORBEVAX® is developed and commercialized by Biological E Limited, an established global vaccine supplier based in Hyderabad, India, using Pichia pastoris yeast strain expressing Receptor Binding Domain (RBD) protein of SARS-CoV-2 engineered by Texas Children's Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine (BCM),
- "The recombinant yeast strains enable production of the RBD protein which can be further utilized by vaccine researchers globally to develop & manufacture effective and low-cost vaccines.
- By providing access to the yeast strains via non-exclusive licensing, we continue our mission to support global vaccine accessibility and availability."
- Biological E subsequently developed large scale manufacturing technology for production of the RBD protein complying with Good Manufacturing Practices (GMP) as well as testing & characterization suitable for use as vaccine antigen.
- The RBD protein was then used as an antigen and formulated with optimized adjuvants (Alum and CpG1018) to develop a COVID-19 candidate vaccine.